Real-World Utilization of Biologic and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs in Psoriatic Arthritis and Axial Spondyloarthritis: Insights from Sweden and Germany 

Analysis of real-world data from Swedish National Registers (2017–2021) and a German insurance claims database (2018–2021) to assess characteristics and dosing patterns in PsA and axSpA patients initiating b/tsDMARDs. Included: 9414 PsA and 7763 axSpA patients in Sweden; 2045 PsA and 1756 axSpA patients in Germany. Despite alignment with European treatment guidelines, treatment patterns differed notably between countries. Further analysis comparing outcomes is warranted to determine real-world effectiveness of divergent approaches.